- Brazil's Temer to leave hospital, return to Brasilia
- Poland gives government key election role, opposition sounds alarm
- Prince Harry and Meghan Markle to wed on May 19, 2018
- Britain's Prince Harry and Meghan Markle to marry on May 19
- Finland lets stores sell stronger drinks, health chiefs complain
- Multi-summit Macron burns energy in hunt for results
- Erdogan says Turkey seeking to annul Trump decision on Jerusalem at U.
- Russian ex-minister Ulyukayev jailed for eight years over $2 million b
- Mexico's Senate passes divisive security law, paving way for final app
- U.S. says concerned about Myanmar's silence over where Reuters journal
- 'Congratulations': EU launches next phase of Brexit
- Novo Nordisk wins EU panel's backing for key diabetes drug
- Pakistani top court rejects bid to bar opposition leader Imran Khan
- Aclaris's drug to treat common skin growth gets FDA nod
- Catalan election to return hung parliament: poll
- Aclaris's drug to treat common growth on skin gets FDA nod
- FDA allows Alnylam to restart hemophilia treatment trials
- U.N. appalled at Iraq's latest mass hanging: spokeswoman
- Why Jerusalem's holy sites are so significant - CNN Video
- Friday protests over Trump's Jerusalem decision
Prescription video games help children with ADHD in trial
LONDON (Reuters) - Playing tailor-made video games can help children with attention deficit hyperactivity disorder (ADHD), according to results from a pivotal clinical trial announced on Monday.
The U.S. company developing the treatment, unlisted Akili, now plans to file for regulatory approval with the U.S. Food and Drug Administration in the first half of 2018, paving the way for what would be the first such “digital” prescription product.
Akili is an affiliate of London-listed PureTech Health.
Cases of ADHD have been rising around the world in recent decades, with children often given drugs to treat the disorder. Akili’s product takes a different approach by using a game to stimulate specific cognitive neural systems in the brain.
In the randomized, controlled trial of 348 children and adolescents with ADHD, Akili’s product AKL-T01 showed a statistically significant improvement compared with an active control in attention performance. The control was also a video game.
Medicating ADHD is big business, with Shire a leading player in the field. Shire is also an investor in Akili.
Reporting by Ben Hirschler; Editing by Mark Potter
Our Standards:The Thomson Reuters Trust Principles.